Junichi Hoshino1, Daniel Muenz2, Jarcy Zee2, Nidhi Sukul3, Elodie Speyer4, Murilo Guedes5, Antonio A Lopes6, Koichi Asahi7, Heleen van Haalen8, Glen James9, Nafeesa Dhalwani10, Roberto Pecoits-Filho11, Brian Bieber2, Bruce M Robinson2, Ronald L Pisoni12. 1. Nephrology Center, Toranomon Hospital, Tokyo, Japan. 2. Arbor Research Collaborative for Health, Ann Arbor, Michigan. 3. Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 4. CESP Centre for Research in Epidemiology and Population Health, Université Paris-Saclay, Université Paris Sud, UVSQ, UMRS 1018, Villejuif, France. 5. School of Medicine, Pontificia Universidade Catolica do Parana, Curitiba, Brazil. 6. Department of Internal Medicine, Federal University of Bahia, Salvador, Bahia, Brazil. 7. Department of Chronic Kidney Disease Initiatives, Fukushima Medical University School of Medicine, Fukushima, Japan. 8. AstraZeneca, Gothenburg, Sweden. 9. AstraZeneca, Cambridge, UK. 10. Evidera, London, UK. 11. Arbor Research Collaborative for Health, Ann Arbor, Michigan; School of Medicine, Pontificia Universidade Catolica do Parana, Curitiba, Brazil. 12. Arbor Research Collaborative for Health, Ann Arbor, Michigan. Electronic address: ronald.pisoni@arborresearch.org.
Abstract
OBJECTIVE: Conflicting findings and knowledge gaps exist regarding links between anemia, physical activity, health-related quality of life (HRQOL), chronic kidney disease (CKD) progression, and mortality in moderate-to-advanced CKD. Using the CKD Outcomes and Practice Patterns Study, we report associations of hemoglobin (Hgb) with HRQOL and physical activity, and associations of Hgb and physical activity with CKD progression and mortality in stage 3-5 nondialysis (ND)-CKD patients. DESIGN AND METHODS: Prospectively collected data were analyzed from 2,121 ND-CKD stage 3-5 patients, aged ≥18 years, at 43 nephrologist-run US and Brazil CKD Outcomes and Practice Patterns Study-participating clinics. Cross-sectional associations were assessed of Hgb levels with HRQOL and physical activity levels (from validated Kidney Disease Quality of Life Instrument and Rapid Assessment of Physical Activity surveys). CKD progression (first of ≥40% estimated glomerular filtration rate [eGFR] decline, eGFR<10 mL/min/1.73 m2, or end-stage kidney disease) and all-cause mortality with Hgb and physical activity levels were also evaluated. Linear, logistic, and Cox regression analyses were adjusted for country, demographics, smoking, eGFR, serum albumin, very high proteinuria, and 13 comorbidities. RESULTS: HRQOL was worse, with severe anemia (Hgb<10 g/dL), but also evident for mild/moderate anemia (Hgb 10-12 g/dL), relative to Hgb>12 g/dL. Odds of being highly physically active were substantially greater at Hgb>10.5 g/dL. Lower Hgb was strongly associated with greater CKD progression and mortality, even after extensive adjustment. Physical inactivity was strongly associated with greater mortality and weakly associated with CKD progression. Possible residual confounding is a limitation. CONCLUSION: This multicenter international study provides real-world observational evidence for greater HRQOL, physical activity, lower CKD progression, and greater survival in ND-CKD patients with Hgb levels >12 g/dL, exceeding current treatment guideline recommendations. These findings help inform future studies aimed at understanding the impact of new anemia therapies and physical activity regimens on improving particular dimensions of ND-CKD patient well-being and clinical outcomes.
OBJECTIVE: Conflicting findings and knowledge gaps exist regarding links between anemia, physical activity, health-related quality of life (HRQOL), chronic kidney disease (CKD) progression, and mortality in moderate-to-advanced CKD. Using the CKD Outcomes and Practice Patterns Study, we report associations of hemoglobin (Hgb) with HRQOL and physical activity, and associations of Hgb and physical activity with CKD progression and mortality in stage 3-5 nondialysis (ND)-CKDpatients. DESIGN AND METHODS: Prospectively collected data were analyzed from 2,121 ND-CKD stage 3-5 patients, aged ≥18 years, at 43 nephrologist-run US and Brazil CKD Outcomes and Practice Patterns Study-participating clinics. Cross-sectional associations were assessed of Hgb levels with HRQOL and physical activity levels (from validated Kidney Disease Quality of Life Instrument and Rapid Assessment of Physical Activity surveys). CKD progression (first of ≥40% estimated glomerular filtration rate [eGFR] decline, eGFR<10 mL/min/1.73 m2, or end-stage kidney disease) and all-cause mortality with Hgb and physical activity levels were also evaluated. Linear, logistic, and Cox regression analyses were adjusted for country, demographics, smoking, eGFR, serum albumin, very high proteinuria, and 13 comorbidities. RESULTS: HRQOL was worse, with severe anemia (Hgb<10 g/dL), but also evident for mild/moderate anemia (Hgb 10-12 g/dL), relative to Hgb>12 g/dL. Odds of being highly physically active were substantially greater at Hgb>10.5 g/dL. Lower Hgb was strongly associated with greater CKD progression and mortality, even after extensive adjustment. Physical inactivity was strongly associated with greater mortality and weakly associated with CKD progression. Possible residual confounding is a limitation. CONCLUSION: This multicenter international study provides real-world observational evidence for greater HRQOL, physical activity, lower CKD progression, and greater survival in ND-CKDpatients with Hgb levels >12 g/dL, exceeding current treatment guideline recommendations. These findings help inform future studies aimed at understanding the impact of new anemia therapies and physical activity regimens on improving particular dimensions of ND-CKDpatient well-being and clinical outcomes.
Authors: Murilo Guedes; Camila R Guetter; Lucas H O Erbano; Andre G Palone; Jarcy Zee; Bruce M Robinson; Ronald Pisoni; Thyago Proença de Moraes; Roberto Pecoits-Filho; Cristina P Baena Journal: BMC Nephrol Date: 2020-07-08 Impact factor: 2.388
Authors: Chuan-Ming Hao; Eric T Wittbrodt; Eirini Palaka; Nicolas Guzman; Alicia Dunn; Susan Grandy Journal: Int J Nephrol Renovasc Dis Date: 2021-02-22
Authors: Brian Czaya; Kylie Heitman; Isaac Campos; Christopher Yanucil; Dominik Kentrup; David Westbrook; Orlando Gutierrez; Jodie L Babitt; Grace Jung; Isidro B Salusky; Mark Hanudel; Christian Faul Journal: Elife Date: 2022-03-18 Impact factor: 8.713
Authors: Steven Fishbane; Mohamed A El-Shahawy; Roberto Pecoits-Filho; Bui Pham Van; Mark T Houser; Lars Frison; Dustin J Little; Nicolas J Guzman; Pablo E Pergola Journal: J Am Soc Nephrol Date: 2021-02-10 Impact factor: 10.121